Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 204 of the 206 references it cites were found in a registry or an index; 68 of the 244 sources its claims cite were checked for support.
Abstract
Objective The aim was to develop clinical practice guidelines on hypertriglyceridemia. Participants The Task Force included a chair selected by The Endocrine Society Clinical Guidelines Subcommittee (CGS), five additional experts in the field, and a methodologist. The authors received no corporate funding or remuneration. Consensus process Consensus was guided by systematic reviews of evidence, e-mail discussion, conference calls, and one in-person meeting. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. Conclusions The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150-999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hypertriglyceridemia (triglycerides of > 1000 mg/dl) be considered a risk for pancreatitis. The Task Force also recommends that patients with hypertriglyceridemia be evaluated for secondary causes of hyperlipidemia and that subjects with primary hypertriglyceridemia be evaluated for family history of dyslipidemia and cardiovascular disease. The Task Force recommends that the treatment goal in patients with moderate hypertriglyceridemia be a non-high-density lipoprotein chole…
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends evaluating and treating hypertriglyceridemia with fasting triglyceride measurement, secondary-cause workup, lifestyle therapy for mild-to-moderate elevations, and combined diet plus drug therapy for severe/very severe hypertriglyceridemia to prevent pancreatitis. It also concludes that triglycerides are associated with cardiovascular risk but whether they are causal remains uncertain.
Key findings
- The guideline recommends screening adults with a fasting lipid panel at least every 5 yr (1/QQEE), basing hypertriglyceridemia diagnosis on fasting rather than nonfasting triglycerides (1/QQQE), and against routine lipoprotein particle heterogeneity measurement (1/QQEE).
- It defines moderate hypertriglyceridemia as 200–999 mg/dl, severe as 1000–1999 mg/dl, and very severe as ≥2000 mg/dl; for severe/very severe hypertriglyceridemia (>1000 mg/dl), it recommends combining dietary fat and simple carbohydrate reduction with drug treatment to reduce pancreatitis risk (1/QQQQ), with fibrate as first-line for triglyceride-induced pancreatitis (1/QQQE).
- Lifestyle therapy is recommended initially for mild-to-moderate hypertriglyceridemia (1/QQEE); for moderate hypertriglyceridemia, the treatment goal is a non-HDL cholesterol level in agreement with NCEP ATP guidelines (1/QQEE); statins should not be used as monotherapy for severe or very severe hypertriglyceridemia but may be useful for moderate hypertriglyceridemia to modify cardiovascular risk (1/QQEE).
- In NHANES 1999–2004, 33% of nearly 6000 participants had serum triglycerides ≥150 mg/dl (42% among those aged ≥60 yr); about 14% had 150–200 mg/dl, 16% had 200–500 mg/dl, and about 2% had >500 mg/dl. Meta-analytic estimates included an adjusted odds ratio of 1.72 (95% CI, 1.56–1.90) for coronary heart disease comparing top vs bottom triglyceride tertiles, and an ERFC hazard ratio of 1.37 (95% CI, 1.31–1.42) after adjustment for nonlipid factors, reduced to 0.99 (95% CI, 0.94–1.05) after adjustment for HDL and non-HDL cholesterol.
Methods
- The Task Force followed the GRADE approach: strong recommendations use “we recommend” and number 1; weak recommendations use “we suggest” and number 2; evidence quality is denoted QEEE (very low), QQEE (low), QQQE (moderate), and QQQQ (high).
- The guideline was developed by a chair selected by The Endocrine Society Clinical Guidelines Subcommittee, five additional experts, and a methodologist; evidence included observational/epidemiological studies and a systematic review/meta-analysis commissioned by The Endocrine Society.
- Funding was derived solely from The Endocrine Society, and the Task Force received no corporate funding or remuneration.
Limitations
- The Task Force states that it acknowledges the observational nature of the available evidence and dependence on epidemiological studies, and that it made several strong recommendations based on assumptions about patients’ values and preferences.
- The paper states that whether serum triglycerides are causally related to atherosclerosis remains to be elucidated, that elevated triglycerides may sometimes be a marker rather than a causal factor, and that there is a lack of clear human data showing triglyceride reductions reduce cardiovascular disease.
- Stated limitations of specific evidence include lack of standardization and reference levels for nonfasting triglycerides, and for the Copenhagen City Heart Study analysis, a small number of subjects with high triglycerides, no adjustment for HDL cholesterol, and lack of fasting triglyceride levels for comparison.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Valid · 24 Not valid · 106 Not checked · 100 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Epidemiological studies vary as to the independent association between large or small LDL and atherosclerotic cardiovascular disease (30).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Partly supportedcites [30] Austin, 1990, Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk., Circulation sourceExperimental — accuracy not yet measured
The introduction (p. 495) reports that the small, dense LDL phenotype was associated with increased myocardial infarction risk, consistent with two previous studies. But the paper does not say that epidemiological studies vary in their findings about an independent association of large or small LDL with cardiovascular disease. Its multivariate analysis examines associations with LDL phenotype, not independent associations with disease. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Prospective multivariate studies demonstrate that large LDL predicts atherosclerosis and coronary heart disease (35,38,39).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Not checked — no full text of the sourcecites [35] Sacks, 2003, Low density lipoprotein and cardiovascular disease: a reappraisal. (Clinical Review 163)., J Clin Endocrinol Metab source
- Partly supportedcites [38] Mora, 2009, Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women., Circulation sourceExperimental — accuracy not yet measured
The Results (Association of NMR Lipoproteins, Lipids, and Apolipoproteins with CVD; page unavailable) report that large LDL particles were significantly associated with incident cardiovascular disease in women when all nine particle subclasses were included in the model. They were not associated with cardiovascular disease in the separate adjusted model. The paper does not establish that large LDL specifically predicts atherosclerosis or coronary heart disease. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [39] Campos, 2001, Low density lipoprotein size, pravastatin treatment, and coronary events., JAMA source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Several reports also show that measurement of apoB is superior to measurement of LDL or even non-HDL cholesterol as an indicator of global CVD risk (40,41).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Not checked — no full text of the sourcecites [40] de Graaf, 2008, A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias., Nat Clin Pract Endocrinol Metab source
- Supportedcites [41] Holewijn, 2010, Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk., J Intern Med source
The Discussion reports that, in this population-based sample, apoB identified people with a compromised cardiovascular risk profile more effectively than non-HDL cholesterol, while LDL cholesterol was least effective. It also reports significantly greater discrimination of prevalent CVD for apoB than for non-HDL cholesterol. The finding is based on this cohort; the authors note that a cited meta-analysis found no difference between apoB and non-HDL cholesterol. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several prospective studies suggest that circulating levels of small, dense LDL particles are better predictors of coronary atherosclerosis, carotid atherosclerosis, and response to therapy than are levels of large, buoyant LDL particles (28,(31)(32)(33).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Partly supportedcites [28] Zambon, 1999, Evidence for a new pathophysiological mechanism for coronary artery regression: hepatic lipase-mediated changes in LDL density., Circulation sourceExperimental — accuracy not yet measured
The Abstract reports prospective associations between LDL size or density and coronary artery disease, and says patients with small, dense LDL responded better to therapy than those with large, buoyant LDL. The Results link changes in LDL buoyancy to changes in coronary stenosis. The cited paper does not address carotid atherosclerosis, so it does not support that part of the claim. Page numbers are unavailable in our copy. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [31] St-Pierre, 2005, Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study., Arterioscler Thromb Vasc Biol source
- Not checked — no full text of the sourcecites [32] Mora, 2007, LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)., Atherosclerosis source
- Partly supportedcites [33] Musunuru, 2009, Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk., Arterioscler Thromb Vasc Biol sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that small and medium LDL particle levels were associated with cardiovascular disease, whereas large LDL particle levels were not significantly related; it also says this pattern agrees with prospective cohorts including a study of carotid atherosclerosis. It does not establish that small, dense LDL levels predict response to therapy better than large LDL levels. Instead, the Discussion proposes evaluating lipoprotein measures in treatment studies as future work. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Prospective studies have indicated that, compared with fasting levels, nonfasting serum triglyceride levels may be a better or similar predictor of CVD events in the general population (15-18).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.2. Evidence
What the sources say
- Not checked — no full text of the sourcecites [15] Nordestgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women., JAMA source
- Not checked — no full text of the sourcecites [16] Bansal, 2007, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women., JAMA source
- Supportedcites [17] Mora, 2008, Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events., Circulation source
The paper’s introductory passage says three studies suggested that nonfasting triglycerides may predict CVD events better than or similarly to fasting levels. Its Results also report a stronger association for nonfasting triglycerides in its prospective cohort of initially healthy women. No page number is available in our copy. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [18] Stalenhoef, 2008, Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small, dense LDL., Curr Opin Lipidol source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
149 more claims · 26 with their cited sources checked
Create a free account to see all 283 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 53
- It may state two separate claims as one. 94
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HTG may result from impaired clearance of TRLs, most often due to pathogenic variants in the lipolytic pathway, ranging from monogenic defects in LPL gene or its cofactors (APOC2, APOA5, LMF1, and GPIHBP1) to polygenic susceptibility, and may be exacerbated by secondary factors such as diabetes, obesity, alcohol use, and certain medications [5, 6].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current management strategies for HTG and mixed dyslipidemia provide limited and inconsistent benefits in TG lowering and cardiovascular outcomes, underscoring the need for more effective and durable approaches targeting TRL and apoB-containing lipoproteins (Filtz et al., 2024; Berglund et al., 2012; Chapman et al., 2011).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Berglund et al., 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A delay in diagnosis may place patients at an increased risk for acute pancreatitis.11”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [11]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The APPROACH trial showed that volanesorsenmediated lowering of plasma apolipoprotein C-III levels in patients with familial chylomicronemia syndrome effectively lowered plasma triglycerides below the threshold of 750 to 880 mg per deciliter”
From Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome (2019) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Acute pancreatitis can lead to chronic pancreatitis, 10,11 signs of exocrine or endocrine pancreatic insufficiency, including pancreatic (type 3c) diabetes, 12 and can be fatal.”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.1. Evidence
“Of subjects with hypertriglyceridemia, about 14% had mild hypertriglyceridemia (150 -200 mg/dl), whereas 16% had triglyceride levels of 200 -500 mg/dl, and about 2% had levels above 500 mg/dl.”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.1. Evidence
“In the National Health and Nutrition Examination Survey (NHANES), 1999 -2004, 33% of the nearly 6000 participants (37% men, 30% women) had serum triglycerides of at least 150 mg/dl (Ն1.7 mmol/liter) (5).”
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860 · cited 7×
“Cosponsoring Associations: American Heart Association, European Society of Endocrinology.”
InfluentialDetection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group (1).”
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Research works printed but not linked: 2
- Assmann, 1993, Results and conclusions of the prospective cardiovascular Munster (PROCAM) study, 19
- Brunzell, 2001, Familial lipoprotein lipase deficiency, ApoC-II deficiency, and hepatic lipase deficiency, 2789
Cited by
Items 101–200 of 886
Liver disease and malnutrition
Pürnak, T., & Yilmaz, Y. N. (2013) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.06.018 · Cited by 78
Nonstatin Therapies for Management of Dyslipidemia: A Review
Sando, K. R., & Knight, M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.001 · Cited by 73
“In practice, omega-3 FAs are commonly recommended for patients at high risk for CVD or hypertriglyceridemia.(2,3,26,27) Omega-3 FAs can be obtained through dietary intake, over-the-counter, or prescription supplementation.”
BackgroundDyslipidemia in Pediatric Type 2 Diabetes Mellitus
Sunil, B., & Ashraf, A. P. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01336-6 · Cited by 79
Hypertriglyceridemia - Common Causes, Prevention and treatment Strategies
Rygiel, K. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x14666180123165542 · Cited by 67
Hansen, S. E. J., Madsen, C. M., Varbo, A., & Nordestgaard, B. G. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz059 · Cited by 72
Rashid, N., Sharma, P. P., Scott, R. D., Lin, K. J., & Toth, P. P. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.02.019 · Cited by 66
Hypertriglyceridemia—causes, significance, and approaches to therapy
Santos-Baez, L. S., & Ginsberg, H. N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00616 · Cited by 66
Joglekar, K., Brannick, B., Kadaria, D., & Sodhi, A. (2017) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817695449 · Cited by 73
Approach to Hypertriglyceridemia in the Pediatric Population
Valaiyapathi, B., Sunil, B., & Ashraf, A. P. (2017) · Pediatrics in Review · doi:10.1542/pir.2016-0138 · Cited by 70
Pothoulakis, I., Paragomi, P., Archibugi, L., Tuft, M., Talukdar, R., Kochhar, R. K., Goenka, M. K., Gulla, A., Singh, V. K., González, J. A., et al. (2020) · Pancreatology · doi:10.1016/j.pan.2020.02.010 · Cited by 72
Gupta, M., Liti, B., Barrett, C., Thompson, P. D., & Fernández, A. B. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.12.006 · Cited by 77
Ito, M. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.012 · Cited by 76
“Low-density lipoprotein cholesterol (LDL-C) and/or non-highdensity lipoprotein cholesterol (non-HDL-C) reductions remain the primary treatment targets for patients with mild to moderate hypertriglyceridemia [5,6,8,9].”
BackgroundInfluentialAkbari, M., Ostadmohammadi, V., Lankarani, K. B., Tabrizi, R., Kolahdooz, F., Khatibi, S. R., & Asemi, Z. (2018) · Metabolism · doi:10.1016/j.metabol.2018.07.002 · Cited by 75
“There are multiple primary and secondary causes of metabolic disturbances related to metabolic syndrome (MetS) including impaired glucose tolerance and hypertriglyceridemia, such as genetics, lifestyle and diet especially obesity and reduced physical activity [1,2].”
Background2015 Korean Guidelines for Management of Dyslipidemia
Committee for Guidelines for Management of Dyslipidemia (2015) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2015.4.1.61 · Cited by 71
Risk factors for cardiovascular disease: renewed interest in triglycerides
Berglund, L., Sacks, F., & Brunzell, J. D. (2013) · Clinical Lipidology · doi:10.2217/clp.12.81 · Cited by 63
Self-citationO’Dea, L. S. L., MacDougall, J., Alexander, V. J., Digenio, A., Hubbard, B., Arca, M., Moriarty, P. M., Kastelein, J. J. P., Bruckert, E., Soran, H., et al. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00214 · Cited by 62
Clinical Study of 224 Patients with Hypertriglyceridemia Pancreatitis
Zhang, X., Li, F., Zhen, Y.-M., Li, A., & Fang, Y. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.161361 · Cited by 63
“[28] Since mild to moderate elevations in TG are seen in the early phase of AP of any etiology in up to 47% of the cases,[29] it is unclear whether HTG is an epiphenomenon or if it is a cause or contributing factor for AP.”
BackgroundMollazadeh, H., Mahdian, D., & Hosseinzadeh, H. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.09.024 · Cited by 67
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61
Alexopoulos, A., Qamar, A., Hutchins, K., Crowley, M. J., Batch, B. C., & Guyton, J. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1136-3 · Cited by 75
Posicionamento sobre o Consumo de Gorduras e Saúde Cardiovascular – 2021
Izar, M. C. D. O., Lottenberg, A. M., Giraldez, V. Z. R., Santos, R. D., Machado, R. M., Bertolami, A., Assad, M. H. V., Saraiva, J. F. K., Faludi, A. Á., Moreira, A. S. B., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201340 · Cited by 142
Zhou, Z., Ryan, J. L., Tonkin, A. M., Zoungas, S., Lacaze, P. A., Wolfe, R. S., Orchard, S. G., Murray, A. M., McNeil, J. J., Yu, C., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207923 · Cited by 69
Jin, M., Peng, J., Zhu, H., Zhang, H. M., Lü, B., Li, Y., Qian, J., Yu, X., & Yang, H. B. (2018) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12659 · Cited by 59
“3 mmol/L.(16) Patients admitted within 3 days from their disease onset were enrolled in this study.”
MethodTherapy of Canine Hyperlipidemia with Bezafibrate
Marco, V. D., Noronha, K. S. M., Casado, T. C., Nakandakare, E. R., Flório, J. C., dos Santos, E. Z., & Gilor, C. (2017) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.14701 · Cited by 61
“Fibrates are the first drug of choice for treatment of moderate-to-severe hyperlipidemia in people.(23,25) In dyslipidemic dogs, the therapeutic effects of fibrates were reported only in isolated cases.”
BackgroundFamilial Combined Hyperlipidemia: Current Knowledge, Perspectives, and Controversies
Bello-Chavolla, O. Y., Kuri-García, A., Ríos-Ríos, M., Vargas-Vázquez, A., Cortés-Arroyo, J. E., Tapia-González, G., Cruz-Bautista, I., & Aguilar-Salinas, C. A. (2018) · Revista de Investigación Clínica · doi:10.24875/ric.18002575 · Cited by 53
Hallensleben, N. D. L., Umans, D. S., Bouwense, S. A. W., Verdonk, R. C., Römkens, T. E. H., Witteman, B. J. M., Schwartz, M. P., Spanier, M., Laheij, R. J. F., van Santvoort, H. C., et al. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619890462 · Cited by 53
Recent advances in understanding and managing acute pancreatitis
Mandalia, A. B., Wamsteker, E., & Dimagno, M. J. (2018) · F1000Research · doi:10.12688/f1000research.14244.2 · Cited by 106
The Genetic Basis of Hypertriglyceridemia
Carrasquilla, G. D., Christiansen, M. R., & Kilpeläinen, T. O. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00939-y · Cited by 62
Lipids in liver transplant recipients
Hüsing, A., Kabar, I., & Schmidt, H. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i12.3315 · Cited by 60
Casanova, M., Medeiros, F., Trindade, M., Cohen, C., Oigman, W., & Neves, M. F. (2016) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2016.10.004 · Cited by 56
Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids
Handelsman, Y., & Shapiro, M. D. (2016) · Endocrine Practice · doi:10.4158/ep161445.ra · Cited by 60
Sex Differences in Insulin Resistance and Cardiovascular Disease Risk
Kim, S. H., & Reaven, G. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1166 · Cited by 58
“In fact, younger women in SSPG-3 were the only group to have mean fasting glucose below the prediabetes cut point (100 mg/dL) and triglyceride concentration below the cut point to define hypertriglyceridemia (150 mg/ dL) (18).”
BackgroundUpdate on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
Treatment options for hypertriglyceridemia: From risk reduction to pancreatitis
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., & Stalenhoef, A. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.002 · Cited by 50
Self-citationAmar, M. J., Sakurai, T., Sakurai-Ikuta, A., Sviridov, D. O., Freeman, L. A., Ahsan, L., & Remaley, A. T. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220418 · Cited by 57
“Hypertriglyceridemia is typically defined as triglycerides (TGs) over 200mg/dl (Berglund et al., 2012) and can be the result of several rare primary genetic defects but ismore commonly due to secondary hypertriglyceridemia caused by obesity, diabetes mellitus, pregnancy, alcohol, and a wide variety…”
BackgroundInfluentialTabrizi, R., Ostadmohammadi, V., Lankarani, K. B., Peymani, P., Akbari, M., Kolahdooz, F., & Asemi, Z. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0779-4 · Cited by 54
“Background There are numerous primary and secondary causes of hypertriglyceridemia and hypercholesterolemia, such as genetics, lifestyle and diet, especially obesity and physical inactivity, diseases, including metabolic syndrome (MetS), hyperinsuliemia, diabetes mellitus, and renal disease [1, 2].”
BackgroundHypertriglyceridemia in Obese Children and Adolescents
Jung, M. K., & Yoo, E.-G. (2018) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2018.27.3.143 · Cited by 52
Patel, R. S., Pasea, L., Soran, H., Downie, P., Jones, R., Hingorani, A. D., Neely, D., Denaxas, S., & Hemingway, H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01525-5 · Cited by 57
“This finding potentially challenges current treatment thresholds, [5, 6] while supporting guidelines advocating intervention at lower triglyceride concentrations[36].”
BackgroundResultde Castro-Orós, I., Cenarro, A., Tejedor, M. T., Baila-Rueda, L., Mateo‐Gállego, R., Lamíquiz-Moneo, I., Pocoví, M., & Civeira, F. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000522 · Cited by 52
Hypertriglyceridemia: the importance of identifying patients at risk
Kushner, P. A., & Cobble, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1243005 · Cited by 47
“CVD, a family history of CVD, or the presence of CVD risk factors) [5,6].”
BackgroundMethodInfluentialGubenšek, J. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02957-3 · Cited by 57
“The 2012 Endocrine Society guidelines only consider very severe HTG (above 2000 mg/dL) as a risk factor for development of pancreatitis [12].”
BackgroundEnkhmaa, B., Surampudi, P. N., Anuurad, E., & Berglund, L. (2015) · Europe PMC (PubMed Central) · Cited by 65
Self-citationKaralis, D. G. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0462-y · Cited by 59
“The AHA [11] and NLA [5] define very high TG as C500 mg/dL, whereas the ES [12] uses a”
BackgroundMethodResultInfluentialOmega-3 Fatty Acids as Druggable Therapeutics for Neurodegenerative Disorders
Chitre, N. M., Moniri, N. H., & Murnane, K. S. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666191114093749 · Cited by 234
Bashir, B., Ho, J. H., Downie, P., Hamilton, P., Ferns, G. A., Datta, D. B. N., Cegla, J., Wierzbicki, A. S., Dawson, C., Jenkinson, F., et al. (2023) · Metabolites · doi:10.3390/metabo13050621 · Cited by 52
Acute pancreatitis associated with severe hypertriglyceridaemia; A retrospective cohort study
Charlesworth, A., Steger, A. C., & Crook, M. A. (2015) · International Journal of Surgery · doi:10.1016/j.ijsu.2015.08.080 · Cited by 47
“Insulin and dextrose infusion can also be used to treat severe hypertriglyceridaemia may activate or release the enzyme lipoprotein lipase [25,26].”
BackgroundPathogenic classification of LPL gene variants reported to be associated with LPL deficiency
Rodrigues, R., Artieda, M., Tejedor, D., Martínez, A., Konstantinova, P. S., Petry, H., Meyer, C., Corzo, D., Sundgreen, C., Klör, H. U., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.015 · Cited by 51
Self-citationInsulin-resistance in paediatric age: Its magnitude and implications
Al‐Beltagi, M., Bediwy, A. S., & Saeed, N. K. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i4.282 · Cited by 70
Current Diagnosis and Management of Primary Chylomicronemia
Okazaki, H., Gotoda, T., Ogura, M., Ishibashi, S., Inagaki, K., Daida, H., Hayashi, T., Hori, M., Masuda, D., Matsuki, K., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17054 · Cited by 48
Zhang, Y., He, W., He, C., Wan, J., Lin, X., Zheng, X., Li, L., Li, X., Yang, X., Yu, B., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1969-3 · Cited by 49
2017 Clinical practice guidelines for dyslipidemia of Korean children and adolescents
Lim, J. S., Kim, E. Y., Kim, J. H., Yoo, J.-H., Yi, K. H., Chae, H. W., Choi, J., Kim, J. Y., & Hwang, I. T. (2020) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2040198.099 · Cited by 47
Li, T., Hu, S., Pang, X., Wang, J., Yin, J., Li, F., Wang, J., Yang, X., Xia, B., Liu, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15012 · Cited by 43
PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia
IuA, K., & Владиславовна, Х. Ю. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0268-2 · Cited by 46
“Nevertheless, despite the Endocrine Society Clinical Practice Guidelines (2012) noting that only mild or moderate hypertriglyceridemia are considered risk factors for cardiovascular disease [57], epidemiological data are increasingly pointing towards severe”
Background2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 61
Chan, K. S., & Shelat, V. G. (2022) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v14.i11.1179 · Cited by 58
Karolczak, K., Kamysz, W., Karafová, A., Drzewoski, J., & Watała, C. W. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.04.010 · Cited by 41
for the BIP Study Group, Arbel, Y., Klempfner, R., Erez, A., Goldenberg, I., Benzekry, S., Shlomo, N., Fisman, E. Z., & Tenenbaum, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0332-6 · Cited by 40
“The current guidelines recommend considering combination fibrate-statin therapy for patients when statin therapy alone is not adequate to achieve lipid goals [29, 32, 34].”
BackgroundBashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
Rotroff, D. M., Pijut, S. S., Marvel, S. W., Jack, J. R., Havener, T. M., Pujol, A., Schlüter, A., Graf, G. A., Ginsberg, H. N., Shah, H., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.798 · Cited by 40
Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids
Burke, M. F., Burke, F. M., & Soffer, D. E. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0700-z · Cited by 44
Ooi, E. M. M., Barrett, P. H. R., & Watts, G. F. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.069 · Cited by 42
Yu, S., Wu, D., Jin, K., Yin, L., Fu, Y., Liu, D., Zhang, L., Yu, X., & Xu, J. (2019) · Medical Science Monitor · doi:10.12659/msm.915526 · Cited by 41
“In addition, previous research showed that severe acute pancreatitis (SAP) accounts for 12~38% of all HTGP patients [5].”
BackgroundYang, X., He, J., Ma, S., Wang, T., Zhu, Q., Cao, F., Li, Y., Yang, C., Chen, C., Lu, G., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01597-4 · Cited by 41
“According to the Endocrine Society Clinical Practice Guidelines [13], HTG level was determined above 1.”
MethodInfluentialThe autonomic nervous system regulates postprandial hepatic lipid metabolism
Bruinstroop, E., la Fleur, S. E., Ackermans, M. T., Foppen, E., Wortel, J., Kooijman, S., Berbée, J. F. P., Rensen, P. C. N., Fliers, E., & Kalsbeek, A. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00614.2012 · Cited by 38
Kumar, N., Chandan, N. K., Gupta, S. K., Bhushan, S., & Patole, P. B. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.737506 · Cited by 44
Utilization of genetic tests: analysis of gene-specific billing in Medicare claims data
Lynch, J. A., Berse, B., Dotson, W. D., Khoury, M. J., Coomer, N. M., & Kautter, J. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.209 · Cited by 36
Hypertriglyceridemia-Related Pancreatitis In Patients With Type 2 Diabetes: Links And Risks
Shemesh, E., & Zafrir, B. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188856 · Cited by 45
“The Endocrine Society clinical practice guidelines proposed defining fasting triglyceride levels between 1000 and 1999 mg/dL as severe HTG and above 2000 mg/dL as very severe HTG, aiming to emphasize the significant increase in the risk for acute pancreatitis associated with these levels.(18) HTG observed in patients…”
BackgroundLu, Z., Li, M., Guo, F., Zhang, G., Song, S., Liu, N., & Wang, D. (2019) · Pancreas · doi:10.1097/mpa.0000000000001463 · Cited by 36
“Elevated TG levels are an established risk factor for acute pancreatitis.(19) The incidence of acute pancreatitis has been shown to increase by the level of initial hypertriglyceridemia.”
BackgroundFeitosa, A. C. R., Barreto, L. T., da Silva, I. M., da Silva, F. F., & Filho, G. S. F. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170070 · Cited by 36
Opel, D., Kramer, O. N., Chevalier, M., Bigby, M., & Albrecht, J. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15207 · Cited by 36
Dhindsa, S., Sharma, A., Al-Khazaali, A., Sitaula, S., Nadella, S., McKee, A. M., Albert, S. G., Bourey, R. E., & Dandona, P. (2019) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz019 · Cited by 37
Heidker, R. M., Caiozzi, G. C., & Ricketts, M. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500795 · Cited by 38
“Cardiovascular disease (CVD) is the number one cause of death worldwide [1].”
BackgroundInfluentialSchioldan, A. G., Gregersen, S., Hald, S. M., Bjørnshave, A., Bohl, M., Hartmann, B., Holst, J. J., Stødkilde‐Jørgensen, H., & Hermansen, K. (2017) · European Journal of Nutrition · doi:10.1007/s00394-016-1369-8 · Cited by 44
Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia
Pirillo, A., & Catapano, A. L. (2013) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(13)70004-7 · Cited by 45
“Treatments of HTG include lifestyle modification for mild-to-moderate HTG and pharmacological therapies for the treatment of high and very high TG levels [12].”
BackgroundGC-MS based metabolomics strategy to distinguish three types of acute pancreatitis
Huang, J., He, D., Chen, L., Dong, C.-Y., Zhang, S.-H., Qin, Y., Yu, R., Ahmed, R., Kuang, J.-J., & Zhang, X. (2019) · Pancreatology · doi:10.1016/j.pan.2019.05.456 · Cited by 38
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Olive oil and postprandial hyperlipidemia: implications for atherosclerosis and metabolic syndrome
la Paz, S. M., Bermúdez, B., Cardelo, M. P., López, S., Abia, R., & Muriana, F. J. G. (2016) · Food & Function · doi:10.1039/c6fo01422d · Cited by 39
Clinical characteristics of Japanese patients with severe hypertriglyceridemia
Tada, H., Kawashiri, M., Nakahashi, T., Yagi, K., Chujo, D., Ohbatake, A., Mori, Y., Mori, S., Kometani, M., Fujii, H., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.05.004 · Cited by 35
Oral retinoids and plasma lipids
Lilley, J. S., Linton, M. F., & Fazio, S. (2013) · Dermatologic Therapy · doi:10.1111/dth.12085 · Cited by 35
“Fibrate therapy follows lifestyle modification (40).”
The burden of familial chylomicronemia syndrome from the patients’ perspective
Gelrud, A., Williams, K. R., Hsieh, A., Gwosdow, A. R., Gilstrap, A., & Brown, A. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1372193 · Cited by 33
“The average patient-reported TGs ranged from 500 to 3100 mg/dL, which is well above the normal range [10].”
BackgroundBlair, H. A., & Dhillon, S. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0090-3 · Cited by 33
Rämö, J. T., Ripatti, P., Tabassum, R., Söderlund, S., Matikainen, N., Gerl, M. J., Klose, C. D., Surma, M. A., Stitziel, N. O., Havulinna, A. S., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012415 · Cited by 35
Haldar, S., Wong, L. H., Tay, S. L., Jacoby, J. J., He, P., Osman, F., Ponnalagu, S., Jiang, Y. R., Lian, H. P. R., & Henry, C. J. (2020) · The Journal of Nutrition · doi:10.1093/jn/nxaa274 · Cited by 31
“Clinically, this volunteer would be classified as having either moderate to severe hypertriglyceridemia (24), and the Endocrine Society Clinical Practice Guidelines recommend “against the routine measurement of lipoprotein particle heterogeneity in patients with hypertriglyceridemia” (25).”
BackgroundZafrir, B., Jubran, A., Hijazi, R., & Shapira, C. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.086 · Cited by 31
Morton, A. M., Furtado, J. D., Lee, J., Amerine, W., Davidson, M. H., & Sacks, F. M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.09.005 · Cited by 33
Self-citationPatni, N., Li, X., ADAMS-HUET, B. A., & Garg, A. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.003 · Cited by 34
Amblee, A. P., Mohananey, D., Morkos, M., Basu, S., Abegunde, A. T., Ganesh, M., Bhalerao, N., George, A. M., Jain, M., & Fogelfeld, L. A. (2018) · Endocrine Practice · doi:10.4158/ep-2017-0178 · Cited by 35
Chen, L., Huang, Y., Yu, H., Pan, K., Zhang, Z., Man, Y., & Hu, D. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01443-7 · Cited by 36
Savinova, O. V., Fillaus, K., Harris, W. S., & Shearer, G. C. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.793 · Cited by 33
“The purpose if our small clinical trial was to assess the effects of combination therapy with fish oil and niacin on the lipid and lipoprotein endpoints in asymptomatic participants with elevated BMI, high TG, and reduced HDL-C (the components of MetSyn), the majority of whom were naïve to lipid lowering medications.”
BackgroundInfluentialFlaig, T., Douros, A., Bronder, E., Klimpel, A., Kreutz, R. H., & Garbe, E. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12456 · Cited by 33
“In the present case, the patient’s AP shows a reasonable time relationship to TCZ intake, the symptoms and triglyceride levels declined after withdrawal of TCZ and it seems unlikely that the patient’s RA or the intake of his concomitant medication caused AP.24 Hypertriglyceridaemia is a well-known AE of TCZ25,26 and a…”
BackgroundInfluentialHypertriglyceridemia Acute Pancreatitis: Animal Experiment Research
Wang, L., Xu, T., Wang, R., Wang, X., & Wu, D. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-06928-0 · Cited by 34
“For example, the American practice guidelines and the Endocrine Society state that TG > 1,000 mg/dL is necessary to cause AP [28].”
BackgroundSue, L. Y., Batech, M., Yadav, D. K., Pandol, S. J., Blumentals, W. A., von Krusenstiern, L. S., Chen, W., & Wu, B. U. (2017) · Pancreas · doi:10.1097/mpa.0000000000000860 · Cited by 31
Effect of Omega-3 Fatty Acid Supplementation on Oxylipins in a Routine Clinical Setting
Schmöcker, C., Zhang, I. W., Kiesler, S., Kassner, U., Ostermann, A. I., Steinhagen‐Thiessen, E., Schebb, N. H., & Weylandt, K. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010180 · Cited by 35
“However, since the pharmaceutical intake of n-3 PUFA is an established treatment for patients with hypertriglyceridemia [17] and is also approved as a secondary prevention after myocardial infarction [18,19], it is of particular interest to assess the effect of n-3 PUFA supplementation on the plasma lipidome in the co…”
BackgroundInteractive effect of high sodium intake with increased serum triglycerides on hypertension
Choi, J. W., Park, J.-S., & Lee, C. H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231707 · Cited by 31
Alfaro‐Viquez, E., Roling, B. F., Krueger, C. G., Rainey, C. J., Reed, J. D., & Ricketts, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190210 · Cited by 37
Chen, W., Fan, S., Xie, X., Xue, N., Jin, X., & Wang, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096056 · Cited by 29
“Within the past three decades, phenoxyalkylcarboxylic acid derivatives (fibrates) have been the most widely used drugs for hypertriglyceridemia [3,5,6].”
BackgroundPostprandial dysmetabolism: Too early or too late?
Pappas, C., Kandaraki, E., Tsirona, S., Kountouras, D., Kassi, G., & Diamanti‐Kandarakis, E. (2016) · HORMONES · doi:10.14310/horm.2002.1697 · Cited by 30
Germ-Free Swiss Webster Mice on a High-Fat Diet Develop Obesity, Hyperglycemia, and Dyslipidemia
Logan, I. E., Bobe, G., Miranda, C. L., Vasquez‐Perez, S., Choi, J., Lowry, M. B., Sharpton, T. J., Morgun, A., Maier, C. S., Stevens, J. F., et al. (2020) · Microorganisms · doi:10.3390/microorganisms8040520 · Cited by 33
Bai, M., Chen, M., Zeng, Q., Lu, S., Li, P., Ma, Z., Lin, N., Zheng, C., Zhou, H., Zeng, S., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15863 · Cited by 35
“According to the 2012 Endocrine Society guidelines, the majority of pregnant women will be diagnosed with hypertriglyceridaemia (Berglund et al., 2012).”
MethodAtherosclerotic cardiovascular disease risk and evidence-based management of cholesterol
Roy, S. (2014) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.132916 · Cited by 33
“…Baseline ALT should be checked before initiation of statin therapy B [56,59] Evaluate for new-onset diabetes while on statin therapy B [41,62] Statins should not be used in women of childbearing potential (pregnancy category X) unless effective contraception is used and they are not…”
Background
Metadata
- Authors
- Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H.
- Affiliations
- University of California, Davis (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- Columbia University (US)
- Harvard University (US)
- Mayo Clinic (US)
- Radboud University Medical Center (NL)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-09-01
- Volume
- 97
- Issue
- 9
- Pages
- 2969-2989
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3431581
- OpenAlex
- W2111416524
- Cited by
- 887
- References
- 206
- Citations by year
- 2026: 55 · 2025: 54 · 2024: 74 · 2023: 62 · 2022: 72 · 2021: 74 · 2020: 83 · 2019: 61 · 2018: 89 · 2017: 50 · 2016: 62 · 2015: 57 · 2014: 48 · 2013: 41
- FWCI
- 47.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- American Heart Association
- European Society of Endocrinology
- National Heart, Lung, and Blood Institute (R01HL045095)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hypertriglyceridemia, triglyceride levels, fasting triglycerides, cardiovascular risk, pancreatitis, secondary hyperlipidemia, familial hypertriglyceridemia, dyslipidemia, non-HDL cholesterol, lifestyle therapy, fibrate therapy
- MeSH terms
- Exercise Therapy, Humans, Terminology as Topic, Triglycerides, Hypertriglyceridemia, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.